The Pistoia Alliance, has announced the results of a survey on the adoption of blockchain in the pharmaceutical and life science industries
Optibrium, Intellegens and Medicines Discovery Catapult have announced that they have been awarded a £1 million grant from Innovate UK to support the development of artificical Intelligence (AI) in drug discovery
Certara has announced that it has Pirana, a product for connecting and organising pharmacometric modelling results as well as providing interfaces to a range of software tools used in pharmacometrics modelling
Optibrium, a developer of software for drug discovery, has announced it has signed a collaboration agreement with Intellegens, a company developing novel artificial intelligence (AI) software
Citoxlab, a CRO for non-clinical research, has announced an investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch (EPO), a CRO providing services for preclinical oncology research
Seattle-based Aptevo Therapeutics, a clinical-stage biotechnology company, is using Genedata Biologics software to accelerate cancer research
A partnership between the University of Essex and Provide aims to improve the Uk's National Health Service (NHS) by implementing an AI-powered decision-making engine to determine the service a patient needs
FhP-AICOS (Fraunhofer AICOS) is using its knowledge in image processing and machine learning in healthcare to build a new solution to tackle cervical cancer, by making screening in low-resource areas easier and less costly
The Pistoia Alliance is now accepting entries for its 2018 President’s Startup Challenge for the next two months with the closing date on Monday, 3rd September 2018
Iris.ai has launched an exclusive pre-sale for its AIUR tokens
As not only the HPC industry but the larger computing ecosystem tries to overcome the slowdown and eventual end of transistor scaling described by Moore’s Law, scientists and researchers are implementing programmes that will define the technologies and new materials needed to supplement, or repla
Architectural specialisation is one option to continue to improve performance beyond the limits imposed by the slow down in Moore’s Law.
As the complexity of both HPC hardware and the challenges that scientists are trying to solve using HPC systems increases, ensuring a system is utilised efficiently is necessary to deliver a computing service with value for money and a high research output.
With data rates increasing and more complex challenges arising in life sciences, Panasas’ Jim Donovan and Dale Brantly discuss the benefits of using HPC for these workloads
